Related Experiment Video
Updated: May 11, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Protocol for identifying genetic modifiers of phenotypes in individuals with disease-associated variants
Corrine Smolen1, Matthew Jensen1, Santhosh Girirajan1
1Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802, USA.
Abstract:
The variable expressivity of disease-associated variants suggests a role for secondary variants in modifying the clinical presentation of these primary variants. Here, we present a protocol for identifying associations of secondary variants with phenotypes. We describe steps for prioritizing distinct classes of secondary variants throughout the genome. We then detail statistical procedures for finding associations of secondary variants and phenotypes in individuals carrying disease-associated variants. For complete details on the use and execution of this protocol, please refer to Jensen et al.1.
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics and Pharmacogenomics: Overview

